TITLE

COMMENTARY: Review: Opioids are more effective than placebo but not other analgesics for chronic noncancer pain

AUTHOR(S)
Carey, Tim; Hill, Chapel; Krebs, Erin
PUB. DATE
November 2006
SOURCE
ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p74
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents the author's comments on whether opioids are more effective than placebo for chronic noncancer pain (CNCP). There were more responders for titrated morphine than for nortriptyline but also 3-fold more dropouts in the morphine group. While opioids may be an option for treating CNCP they should not be considered the first or best option.
ACCESSION #
23245709

 

Related Articles

  • Review: Opioids are more effective than placebo but not other analgesics for chronic noncancer pain.  // ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p74 

    The article presents information on a study that was conducted to examine whether opioids are more effective than placebo for chronic noncancer pain. Around 34 randomized controlled trials were included in the meta-analysis. Weak opioids and strong opioids were compared with placebo and other...

  • Strong opioids for cancer pain. Makin, Matthew K. // Journal of the Royal Society of Medicine;Jan2001, Vol. 94 Issue 1, p17 

    The article offers information on strong opioids as alternative therapeutic agent in managing cancer pain aside from morphine. It has been noted that strong opioid is the only therapeutic agent to have shown sufficient advantages in managing chronic cancer pain other than morphine since it...

  • Cancer pain management-current status. Thapa, Deepak; Rastogi, V.; Ahuja, Vanita // Journal of Anaesthesiology Clinical Pharmacology;Apr2011, Vol. 27 Issue 2, p162 

    Cancer pain is still one of the most feared entities in cancer and about 75% of these patients require treatment with opioids for severe pain. The cancer pain relief is difficult to manage in patients with episodic or incidental pain, neuropathic pain, substance abuse and with impaired cognitive...

  • Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review. Bell, R. F.; Wisløff, T.; Eccleston, C.; Kalso, E.; Wisløff, T // British Journal of Cancer;6/5/2006, Vol. 94 Issue 11, p1559 

    This qualitative systematic review of the clinical methodology used in randomised, controlled trials of oral opioids (morphine, hydromorphone, oxycodone) for cancer pain underlines the difficulties of good pain research in palliative care. The current literature lacks placebo-controlled...

  • Disruption of opioid-induced placebo responses by activation of cholecystokinin type-2 receptors. Benedetti, Fabrizio; Amanzio, Martina; Thoen, Wilma // Psychopharmacology;Feb2011, Vol. 213 Issue 4, p791 

    Rationale: Placebos are known to induce analgesia through the activation of μ-opioid receptors in some circumstances, such as after morphine pre-conditioning, an effect that is blocked by opioid antagonists. Objectives: On the basis of the anti-opioid action of cholecystokinin, here we tested...

  • The role of opioids in cancer pain. Quigley, Columbia // BMJ: British Medical Journal (International Edition);10/8/2005, Vol. 331 Issue 7520, p825 

    Discusses the use of opioids in managing cancer pain. Suggestion that pain is a subjective experience, influenced by physical, psychological, social, and spiritual factors; List of the goals of managing cancer pain; Reference to the fact that treatment of pain is based on the World Health...

  • Fentanyl Sublingual: In Breakthrough Pain in Opioid-Tolerant Adults with Cancer.  // Drugs;2010, Vol. 70 Issue 17, p2281 

    No abstract available.

  • Long-acting opioid for continuous pain relief.  // Clinical Advisor;Nov2009, Vol. 12 Issue 11, p16 

    The article offers new drug information on Embeda, a long-acting opioid indicated for severe pain management from King Pharmaceuticals Inc. The drug comprises pellets of an extended-release formulation of morphine enveloping the core of naltrexone. It is stated that naltrexone is designated to...

  • Quality assurance in the prescribing of patient-controlled analgesia and long-acting opioids. Lutomeski, Dave M.; Niemeyer, Stacie; Payne, Christine; Pruemer, Jane // American Journal of Health-System Pharmacy;7/15/2003, Vol. 60 Issue 14, p1476 

    The International Association for the Study of Pain defines pain as an unpleasant sensory or emotional experience associated with actual or potential tissue damage. Inadequate pain control is common among hospitalized patients. Two major advances in pain management are patient-controlled...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics